AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

While presenting the data at this year's American Society of Clinical Oncology (ASCO) annual meeting, Peter Voorhees, MD, of ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Myelodysplastic syndromes (MDS) are a group of disorders that typically arise in adulthood, especially after the age of 70, ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...

AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer ...